Combinatorial immunotherapeutic methods and compositions for pancreatic ductal adenocarcinoma treatment

Abstract

Aspects of the present disclosure are directed to immunotherapeutic methods for treating a subject having PDAC. Disclosed are methods comprising treatment with two or more immunotherapeutic agents for generating an effective immune response to PDAC. Certain aspects relate to methods comprising the use of a LAG-3 antagonist and a 41BB agonist, in some cases together with a chemokine receptor inhibitor, for the treatment of PDAC. Also disclosed are compositions comprising a LAG-3 antagonist and a 41BB agonist. In some cases the disclosed compositions further comprise a chemokine receptor inhibitor.

Dependencies are inferred from the claim text.